Insulin-sensitive obesity in humans - a 'favorable fat' phenotype?

Trends in Endocrinology and Metabolism

Volumn 23, Issue 3, 2012, Pages 116-124

  Samocha Bonet, D ^a,b   Chisholm, D J ^a,b   Tonks, K ^a,b,c   Campbell, L V ^a,b,c   Greenfield, J R ^a,b,c  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHEMOKINE; INSULIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADIPOCYTE; ADIPOSE TISSUE; BARIATRIC SURGERY; BODY MASS; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; ENERGY BALANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPOGENESIS; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE;

ADIPOCYTES; ANIMALS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; OBESITY; PHENOTYPE;

EID: 84857686899     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.12.005     Document Type: Review

References (79)

1. Karelis A.D. Metabolically healthy but obese individuals. Lancet 2008, 372:1281-1283.
2. Pataky Z., et al. Open questions about metabolically normal obesity. Int. J. Obes. (Lond.) 2010, 34(Suppl. 2):S18-S23.
3. Sims E.A. Are there persons who are obese, but metabolically healthy?. Metabolism 2001, 50:1499-1504.
4. Primeau V., et al. Characterizing the profile of obese patients who are metabolically healthy. Int. J. Obes. (Lond.) 2011, 35:971-981.
5. Alberti K.G.M.M., et al. Harmonizing the metabolic syndrome. Circulation 2009, 120:1640-1645.
6. Stefan N., et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 2008, 168:1609-1616.
7. Arnlov J., et al. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diab. Care 2011, 34:61-65.
8. Meigs J.B., et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J. Clin. Endocrinol. Metab. 2006, 91:2906-2912.
9. Arnlov J., et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010, 121:230-236.
10. St-Pierre A.C., et al. Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ 2005, 172:1301-1305.
11. Calori G., et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals. Diab. Care 2011, 34:210-215.
12. Kuk J.L., Ardern C.I. Are metabolically normal but obese individuals at lower risk for all-cause mortality?. Diab. Care 2009, 32:2297-2299.
13. Marini M.A., et al. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diab. Care 2007, 30:2145-2147.
14. Sparks L.M., et al. Effect of adipose tissue on the sexual dimorphism in metabolic flexibility. Metabolism 2009, 58:1564-1571.
15. Rosenbaum M., et al. Sexual dimorphism in circulating leptin concentrations is not accounted for by differences in adipose tissue distribution. Int. J. Obes. Relat. Metabol. Disord. 2001, 25:1365-1371.
16. Swarbrick M.M., Havel P.J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab. Syndr. Relat. Disord. 2008, 6:87-102.
17. Mittelstrass K., et al. Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet. 2011, 7:e1002215.
18. Moro C., et al. Influence of gender, obesity, and muscle lipase activity on intramyocellular lipids in sedentary individuals. J. Clin. Endocrinol. Metab. 2009, 94:3440-3447.
19. Jennings C.L., et al. Determinants of insulin-resistant phenotypes in normal-weight and obese Black African women. Obesity 2008, 16:1602-1609.
20. Straznicky N.E., et al. Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. Am. J. Clin. Nutr. 2009, 89:27-36.
21. Messier V., et al. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity (Silver Spring) 2010, 18:911-917.
22. Ukropcova B., et al. Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor. J. Clin. Invest. 2005, 115:1934-1941.
23. Heilbronn L.K., et al. Impaired fat oxidation after a single high-fat meal in insulin-sensitive nondiabetic individuals with a family history of type 2 diabetes. Diabetes 2007, 56:2046-2053.
24. Ukropcova B., et al. Family history of diabetes links impaired substrate switching and reduced mitochondrial content in skeletal muscle. Diabetes 2007, 56:720-727.
25. Weiss R., et al. The 'obese insulin-sensitive' adolescent: importance of adiponectin and lipid partitioning. J. Clin. Endocrinol. Metab. 2005, 90:3731-3737.
26. Brochu M., et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women?. J. Clin. Endocrinol. Metab. 2001, 86:1020-1025.
27. Demerath E.W., et al. Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. Am. J. Clin. Nutr. 2008, 88:1263-1271.
28. Klein S., et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diab. Care 2007, 30:1647-1652.
29. Kabir M., et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E454-E461.
30. Karelis A.D., et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J. Clin. Endocrinol. Metab. 2005, 90:4145-4150.
31. Larson-Meyer D.E., et al. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diab. Care 2006, 29:1337-1344.
32. Kloting N., et al. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E506-E515.
33. O'Connell J., et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS ONE 2010, 5:e9997.
34. McLaughlin T., et al. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 2007, 50:1707-1715.
35. Rabe K., et al. Adipokines and insulin resistance. Mol. Med. 2008, 14:741-751.
36. Ahima R.S., Lazar M.A. Adipokines and the peripheral and neural control of energy balance. Mol. Endocrinol. 2008, 22:1023-1031.
37. Genelhu V.A., et al. Not all obese subjects of multiethnic origin are at similar risk for developing hypertension and type 2 diabetes. Eur. J. Intern. Med. 2009, 20:289-295.
38. Graham T.E., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 2006, 354:2552-2563.
39. Sell H., Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?. Proc. Nutr. Soc. 2009, 68:378-384.
40. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29:415-445.
41. Cinti S., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46:2347-2355.
42. Harman-Boehm I., et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab. 2007, 92:2240-2247.
43. Cancello R., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005, 54:2277-2286.
44. Viardot A., et al. The effects of weight loss and gastric banding on the innate and adaptive immune system in type 2 diabetes and prediabetes. J. Clin. Endocrinol. Metab. 2010, 95:2845-2850.
45. Kraegen E.W., et al. Muscle insulin resistance: a case of fat overconsumption, not mitochondrial dysfunction. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7627-7628.
46. Korenblat K.M., et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134:1369-1375.
47. Fabbrini E., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:15430-15435.
48. Leavens K.F., Birnbaum M.J. Insulin signaling to hepatic lipid metabolism in health and disease. Crit. Rev. Biochem. Mol. Biol. 2011, 46:200-215.
49. van der Meer R.W., et al. Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men. J. Clin. Endocrinol. Metab. 2008, 93:2702-2708.
50. Kirk E., et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009, 136:1552-1560.
51. Samuel V.T., et al. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010, 375:2267-2277.
52. Cowart L.A. Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol. Metab. 2009, 20:34-42.
53. Puri P., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
54. Kumashiro N., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16381-16385.
55. Savage D.B., et al. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 2007, 87:507-520.
56. McGarry J.D. Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
57. Bachmann O.P., et al. Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 2001, 50:2579-2584.
58. Goodpaster B.H., et al. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 2001, 86:5755-5761.
59. Skovbro M., et al. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 2008, 51:1253-1260.
60. Adams J.M., et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004, 53:25-31.
61. Straczkowski M., et al. Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes. Diabetologia 2007, 50:2366-2373.
62. Anastasiou C.A., et al. Diabetes mellitus is associated with increased intramyocellular triglyceride, but not diglyceride, content in obese humans. Metabolism 2009, 58:1636-1642.
63. Coen P.M., et al. Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 2010, 59:80-88.
64. van der Zijl N.J., et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with impaired glucose metabolism. J. Clin. Endocrinol. Metab. 2011, 96:459-467.
65. Lim E.L., et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011, 54:2506-2514.
66. Wiesner P., et al. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 2009, 50:574-585.
67. Kotronen A., et al. Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity 2010, 18:937-944.
68. Karelis A.D., et al. Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 2008, 51:1752-1754.
69. Kantartzis K., et al. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia 2011, 54:864-868.
70. Shin M.J., et al. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int. J. Obes. 2006, 30:1529-1534.
71. Janiszewski P.M., Ross R. Effects of weight loss among metabolically healthy obese men and women. Diab. Care 2010, 33:1957-1959.
72. Sesti G., et al. Effects of weight loss in metabolically healthy obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. PLoS ONE 2011, 6:e17737.
73. Samocha-Bonet D., et al. A family history of type 2 diabetes increases risk factors associated with overfeeding. Diabetologia 2010, 53:1700-1708.
74. Eckel R.H., et al. The metabolic syndrome. Lancet 2010, 375:181-183.
75. Bergman R.N., et al. Assessment of insulin sensitivity in vivo. Endocr. Rev. 1985, 6:45-86.
76. Tripathy D., et al. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diab. Care 2004, 27:2204-2210.
77. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diab. Care 1999, 22:1462-1470.
78. Kuk J.L., Ardern C.I. Influence of age on the association between various measures of obesity and all-cause mortality. J. Am. Geriatr. Soc. 2009, 57:2077-2084.
79. Messier V., et al. Metabolically healthy but obese individuals: relationship with hepatic enzymes. Metabolism 2010, 59:20-24.